Novel Incretin Therapies Show Strong Cardiovascular Benefits for Type 2 Diabetes

Individuals with Type 2 Diabetes (T2D) face a significantly elevated risk of cardiovascular disease (CVD), including heart attacks, strokes, and heart failure, which remains a leading cause of morbidity and mortality. Traditional diabetes treatments primarily focus on glycemic control, but recent advancements in incretin-based therapies have shown promise beyond blood sugar management. Despite growing evidence, there was a need for a comprehensive, early systematic review to consolidate the current understanding of the cardiovascular impact of these novel incretin therapies.

The systematic review highlighted that studies consistently demonstrated significant cardiovascular benefits, particularly with GLP-1 receptor agonists (GLP-1RAs). Pooled data indicated a substantial reduction in major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, often by 14% to 20% compared to placebo or other anti-diabetic treatments. Furthermore, GLP-1RAs were associated with a 12% to 15% lower risk of all-cause mortality and a 13% to 17% reduction in cardiovascular death. The most compelling finding was the consistent evidence that GLP-1 receptor agonists offer robust cardioprotective effects, significantly lowering the risk of serious heart-related events in patients with Type 2 Diabetes. In contrast, DPP-4 inhibitors were generally found to be cardiovascularly safe and non-inferior to placebo, meaning they did not increase cardiovascular risk, but they typically showed a more neutral effect on MACE, with no statistically significant reduction observed across most studies. The benefits of GLP-1RAs were particularly pronounced in patients with established atherosclerotic cardiovascular disease, showing up to a 26% reduction in MACE in some subgroups.